Wen-Cheng Lu

Wen-Cheng Lu is a Scientist II and Bio Safety Officer at Rgenta Therapeutics Inc., where research focuses on developing oral, small-molecule RNA-targeting medicines for oncology and neurological disorders. Previous experience includes a Postdoctoral Fellowship at Indiana University Bloomington, where significant contributions included identifying HSF1 gene expression as a prognostic indicator for breast cancer and studying transcription regulation. At UT Southwestern Medical Center, Lu pioneered research on HIF-2α as a therapeutic target for head and neck cancer, collaborating on projects with Peloton Therapeutics. Lu's doctoral research at National Yang Ming University unveiled a novel tumor suppressor gene, ARID1A, and an oncogenic signaling pathway. Early career experience includes clinical analyses at Taipei Medical University Hospital and technical support at National Taiwan University Hospital. Educational background includes a PhD and Master's degree in Oral Biology from National Yang Ming University and a Bachelor's degree in Medical Laboratory Science and Biotechnology from Taipei Medical University.